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One of the two major endocannabinoids, 2-arachidonoylglycerol (2-AG), serves as a 
retrograde messenger at various types of synapses throughout the brain. Upon 
postsynaptic activation, 2-AG is released immediately after de novo synthesis, activates 
presynaptic CB1 cannabinoid receptors, and transiently suppresses neurotransmitter 
release. When CB1 receptor activation is combined with some other factors such as 
presynaptic activity, the suppression is converted to a long-lasting form. Whereas 2-AG 
primarily transmits a rapid, transient, point-to-point retrograde signal, the other major 
endocannabinoid, anandamide, may function as a relatively slow retrograde or 
non-retrograde signal or as an agonist of the vanilloid receptor. The endocannabinoid 
system can be up- or down-regulated by a variety of physiological and environmental 




Endocannabinoids retrogradely modulate synaptic transmission widely throughout the 
central nervous system [1-5]. They are released from postsynaptic neurons, activate 
presynaptic CB1 cannabinoid receptors, and suppress transmitter release either 
transiently (endocannabinoid-mediated short-term depression; eCB-STD) or persistently 
(endocannabinoid-mediated long-term depression; eCB-LTD). The eCB-STD and 
eCB-LTD are induced at various types of GABAergic and glutamatergic synapses 
throughout the brain. The ability of each synapse to express eCB-STD/LTD depends 
primarily on whether the presynaptic terminal expresses CB1 receptors. In addition to 
their well-established functions as retrograde messengers, endocannabinoids might also 
function in non-retrograde manners [4]. In the last few years evidence has also 
accumulated to suggest that the endocannabinoid signaling system itself is regulated by 
various factors [6]. In this article, we review recent advances in the molecular 
mechanisms of endocannabinoid signaling and its plastic changes induced by 
neuromodulators and environmental factors.  
 
Standard 2-AG model of eCB-STD 
The molecular mechanisms of endocannabinoid release involved in eCB-STD have 
been studied in a variety of preparations. Here we show the standard 2-AG model (Fig. 
1), which can explain most, if not all, results of electrophysiological studies [1-5]. The 
conditions that induce the production and release of 2-AG are mechanistically classified 




endocannabinoid release, CaER), activation of Gq/11-coupled receptors (basal 
receptor-driven endocannabinoid release, basal RER), and the combination of these two 
(Ca2+-assisted RER) [1,2,6]. After released from postsynaptic neurons, 2-AG activates 
presynaptic CB1 receptors and suppresses transmitter release. Termination of the 
retrograde signal depends on degradation of 2-AG by monoacylglycerol lipase (MGL). 
Although the expression of MGL is highly heterogeneous [7,8], 2-AG is degraded in a 
synapse non-specific manner by MGL concentrated in particular cell types [8].  
The CaER is responsible for the eCB-STD induced by depolarizing a 
postsynaptic neuron, which is termed DSI (depolarization-induced suppression of 
inhibition) or DSE (depolarization-induced suppression of excitation) for inhibitory or 
excitatory synapses, respectively. When depolarization causes a large, transient increase 
in [Ca2+]i to micromolar levels through activation of voltage-gated Ca
2+ channels, 
diacylglycerol (DG) is produced through some as yet unidentified mechanism (Fig. 1A, 
red arrows). DG is then converted to 2-AG by diacylglycerol lipase α (DGLα). The 
basal RER is responsible for the eCB-STD induced by activation of Gq/11-coupled 
receptors, such as group I metabotropic glutamate receptors (mGluRs) or M1/M3 
muscarinic acetylcholine receptors (mAChRs), without need of postsynaptic Ca2+ 
elevation. Many other receptors have also been reported to induce RER, which include 
5-HT2-type serotonin receptors, protease-activated receptor 1 (PAR1), and the receptors 
for orexin, oxytocin and CCK [3]. When Gq/11-coupled receptors are activated, DG is 
produced by PLCβ, the subtype of which depends on brain areas (Fig. 1A, blue arrows). 
DG is then converted to 2-AG by DGLα. The Ca2+-assisted RER accounts for the 
eCB-STD induced by the combination of a small increase in [Ca2+]i and weak receptor 
activation, both of which can be subthreshold for triggering endocannabinoid release. 
This synergistic effect can be explained by the Ca2+ dependency of receptor-driven 
PLCβ stimulation [9-11] (Fig. 1A, green arrow).  
More physiological ways of inducing eCB-STD are via synaptic activity 
(synaptically-driven eCB-STD) [1] (Fig. 1B). If glutamate is released from excitatory 
presynaptic terminals in a sufficient amount to induce postsynaptic Ca2+ elevation 
and/or mGluR activation, 2-AG is released through the mechanism for CaER, basal 
RER or Ca2+-assisted RER. Excitatory synaptic activity is therefore potentially effective 
in inducing 2-AG release. Synaptically-driven eCB-STD can be either homosynaptic 
(Fig. 1B, red arrow) or heterosynaptic [1] (Fig. 1B, blue arrow). 
The standard 2-AG model described above is supported by a considerable 
number of studies. DSI, DSE, receptor-driven eCB-STD and synaptically-driven 
eCB-STD are all inhibited by pharmacological blockade of DGL [12] and genetic 
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deletion of DGLα [13-15]. The mGluR- or mAChR-driven eCB-STD is blocked by 
genetic deletion of PLCβ1 for hippocampal neurons [9] or PLCβ4 for cerebellar 
Purkinje cells [10]. The termination of DSI/DSE is prolonged by genetic deletion [8,16] 
and pharmacological blockade of 2-AG hydrolyzing enzyme (MGL), but not 
anandamide (another major endocannabinoid) hydrolyzing enzyme (fatty acid amide 
hydrolase, FAAH) [17]. 
 
On-demand vs. pre-formed 
It is generally thought that 2-AG is not stored in neurons, but synthesized on 
demand upon stimulation. However, this “on-demand synthesis model” was challenged 
by an alternative model that 2-AG is pre-formed by DGLα, pooled within cells, and 
mobilized from this hypothetical pre-formed 2-AG pools upon stimulation without the 
contribution of DGLα [18,19]. This model was developed to reconcile the apparent 
discrepancy in the experimental results between genetic and pharmacological blockade 
of DGL. DGLα knockout mice were generated independently by three groups, and they 
all exhibit complete loss of eCB-STD [13-15]. In contrast, the reported effects of acute 
pharmacological blockade of DGL were highly controversial [19]. A classical DGL 
inhibitor, tetrahydrolipstatin (THL), inhibited eCB-STD in some studies, but not in 
others. Inconsistent results were also observed with a novel potent DGL inhibitor, 
OMDM-188. OMDM-188 failed to inhibit DSI in one study [20], whereas it inhibited 
DSI but not mGluR-driven STD in another study [21]. More recently, however, effects 
of OMDM-188 on multiple types of eCB-STD including CaER, basal RER, 
Ca2+-assisted RER and synaptically-driven eCB release were systematically reexamined 
in acute slices of the hippocampus, cerebellum and striatum and in cultured 
hippocampal neurons [12]. The data clearly demonstrate that DSI, DSE, receptor-driven 
eCB-STD and synaptically-driven eCB-STD in these preparations are consistently 
blocked by the treatment with OMDM-188 [12]. Importantly, application of 
OMDM-188 as short as 2 min was sufficient to block DSI in cultured hippocampal 
neurons [12]. This study has confirmed that there is no discrepancy in the results 
between genetic and pharmacological blockade of DGL, supporting the “on-demand 
synthesis model” rather than the “pre-formed pool model”. 
Given that the “on-demand synthesis model” is correct, why were DGL 
inhibitors ineffective in blocking eCB-STD in some studies? One possibility is 
insufficient penetration of the inhibitors. Since THL and OMDM-188 are highly 
lipophilic, they are difficult to penetrate into brain slices. The effectiveness of these 
DGL inhibitors therefore depends on whether their targets (e.g., soma or dendrites) are 
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located near the surface or in the depth of slices. The effectiveness of THL and 
OMDM-188 also depends on whether or not DGL activity is rate limiting for 2-AG 
production. If DGL activity is rate limiting for CaER, but not for RER, these two types 
of eCB-STD can have different sensitivity to the DGL inhibitors, as previously reported 
[21]. Whether the suppression of synaptic transmission by 2-AG is maximal or 
submaximal is also a key factor determining the effectiveness of DGL inhibitors. The 
inconsistent results of pharmacological studies might result from these differences. 
 
Standard 2-AG model of eCB-LTD 
eCB-LTD is induced mostly by repetitive afferent stimulation with or without 
postsynaptic depolarization, but also by postsynaptic firing [1,4,22,23]. Most types of 
eCB-LTD are mediated by 2-AG. It is generally thought that eCB-LTD and eCB-STD 
share the same molecular mechanisms for 2-AG release, that is, CaER, basal RER and 
Ca2+-assisted RER. Typically, afferent stimulation causes glutamate release from 
excitatory presynaptic terminals, activates AMPA receptors and mGluRs on the 
postsynaptic membrane, and induces 2-AG release. 2-AG then activates CB1 receptors 
on the same presynaptic terminals releasing glutamate (homosynaptic) (Fig. 2, red 
arrow) or neighboring presynaptic terminals (heterosynaptic) (Fig. 2, blue arrow). 
 Although presynaptic mechanisms of eCB-LTD have not been fully elucidated, 
inhibition of the cAMP/PKA pathway seems to be crucial [4]. Involvement of 
calcineurin, RIM1α and Rab3 has also been suggested [4]. In most if not all cases, 
activation of CB1 receptors is not enough to induce LTD, and an additional presynaptic 
mechanism(s) is required [24], such as presynaptic electrical activity [25,26], Ca2+ 
elevation [25,26], NMDA receptor activation [27], M2 receptor activation [28] and/or 
D2 receptor activation [29,30] (Fig. 2). This associative feature may ensure the selective 
induction of eCB-LTD at the active synapses. 
 
Contribution of anandamide to endocannabinoid signaling 
The other major endocannabinoid, anandamide, also contributes to the modulation of 
synaptic transmission (Fig. 3). Several recent studies reported anandamide-mediated 
LTD [31-35] (Fig. 3A). Lerner and Kreitzer reported two types of eCB-LTD in medium 
spiny neurons (MSNs) driving the indirect pathway in the dorsolateral striatum [31]. 
Low frequency stimulation induces 2-AG-mediated LTD, whereas high frequency 
stimulation induces CB1-dependent, anandamide-mediated LTD [31] (Fig. 3A, 
eCB-LTD). Anandamide may contribute to LTD not only as a cannabinoid agonist but 
also as an agonist for transient receptor potential vanilloid receptor type 1 (TRPV1). In 
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indirect pathway MSNs of the nucleus accumbens, Grueter et al. suggested that low 
frequency stimulation induces anandamide-mediated LTD, partly by activating 
presynaptic CB1 receptors (Fig. 3A, eCB-LTD) and partly by activating postsynaptic 
TRPV1 channels (Fig. 3A, TRPV1-LTD) [32]. In the dentate gyrus, Chavez et al. 
reported that pairing stimulation induces CB1-independent, TRPV1-dependent LTD, 
which is expressed postsynaptically and mediated by anandamide [33]. On the other 
hand, Puente et al. suggested that 2-AG mediates both eCB-STD and eCB-LTD in the 
striatum, whereas 2-AG and anandamide mediate eCB-STD and TRPV1-LTD, 
respectively, in the extended amygdala [34]. 
Anandamide may also generate the endocannabinoid tone (Fig. 3B) which 
contributes to homeostatic plasticity in the hippocampus [36] and the regulation of 
hypothalamic-pituitary-adrenal (HPA) axis activity in the amygdala [37] (Fig. 4A). Of 
note, chronic MGL blockade (continuous elevation of 2-AG) causes down-regulation of 
CB1 receptors and functional antagonism of the endocannabinoid system, whereas 
blockade of FAAH (continuous elevation of anandamide) causes sustained agonism 
without down-regulation of CB1 [38]. This finding implies that anandamide has an 
advantage over 2-AG for functioning as a tonic signal. Taking all these findings into 
account, it is conceivable that the two major endocannabinoids, 2-AG and anandamide, 
mediate different types of signals for synaptic modulation [5,38]. 2-AG primarily 
transmits a rapid, transient, point-to-point retrograde signal, whereas anandamide may 
function as a relatively slow, retrograde or non-retrograde signal or as a vanilloid 
agonist.  
As described above, there are many studies of the functional roles of 
anandamide. It should be noted, however, that the evidence for the involvement of 
anandamide in synaptic plasticity is largely indirect, because enzymatic pathways for 
anandamide production are complex and not fully understood. In some studies, the 
contribution of anandamide was suggested principally by the ineffectiveness of DGL 
inhibitors. Considering the fact that pharmacological results with DGL inhibitors have 
been highly controversial and are not as reliable as genetic manipulations, experimental 
data should be interpreted with caution. More direct, convincing evidence will be 
required in future studies.  
 
Other possible mechanisms 
Several additional mechanisms have been suggested to contribute to endocannabinoid 
signaling, including (1) N-arachidonoyldopamine (NADA) [39], (2) glial [40-42] and 
(3) mitochondrial [43] CB1 receptors, (4) FAAH-like anandamide transporter (FLAT) 
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[44] and (5) PLA2 [45,46]. (1) NADA, like anandamide, is an agonist at both 
cannabinoid receptors and TRPV1 channels. Recently, it was reported that NADA is 
tonically released from dopamine neurons, but not neighboring GABAergic neurons, to 
suppress their inhibitory inputs in the Substantia Nigra pars compacta [39]. (2) 
Timing-dependent LTD at cortical excitatory synapses has been shown to require the 
activation of CB1 receptors, which is believed to be located on presynaptic terminals 
(Fig. 2). This hypothesis was challenged by a recent study, which suggested that the 
CB1 receptors mediating LTD are not located on presynaptic terminals, but on 
perisynaptic astrocyte processes [41]. (3) Using mitochondrial fractions and anti-CB1 
polyclonal antibodies, it was shown that CB1 receptors are expressed on mitochondrial 
membranes and are involved in the regulation of neuronal energy metabolism [43]. 
However, these findings were questioned by a more recent study [47], which has 
demonstrated that the previously used anti-CB1 antibodies can bind to the mitochondrial 
protein stomatin-like protein 2, and the previously reported effects of cannabinoid 
agonist on mitochondrial respiration can be replicated in synaptosome-enriched, but not 
pure mitochondrial preparations. (4) FLAT was reported as a critical molecular 
component of anandamide transport in neural cells [44]. The study showed that FLAT is 
a catalytically silent splice variant of FAAH, is expressed robustly throughout the brain, 
and facilitates the translocation of anandamide into cells. A more recent study, however, 
suggested that FLAT does not serve as a global intracellular anandamide carrier [48]. 
The study showed that the expression of FLAT is very low in the brain, and that 
overexpressed FLAT displays residual catalytic activity, suggesting that its capability to 
potentiate anandamide uptake may stem from its enzymatic rather than transport activity. 
(5) A recent study using PLA2-knockout mice proposed that Ca
2+ elevation activates 
PLA2 to liberate arachidonic acid which is then converted to 2-AG and induces DSE in 
cerebellar Purkinje cells [45]. However, since this result cannot be reconciled with the 
standard 2-AG model (Fig. 1A) that is supported by a large number of previous studies, 
further careful studies are required to judge the validity of the result. 
 
Regulation and plasticity of the endocannabinoid system 
The endocannabinoid system depends on many molecular elements, including Ca2+ 
channels, various types of Gq/11-coupled receptors, PLCβ, DGLα, MGL and CB1 
receptor. Thus, any changes in their functional activities or expression levels influence 
the endocannabinoid system. Evidence has accumulated to suggest that the 
endocannabinoid system is regulated by various postsynaptic and presynaptic receptors, 
and also influenced by environmental and pathological factors [6].  
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Postsynaptic and presynaptic receptors can regulate endocannabinoid release 
and CB1 signaling, respectively. In the striatum, postsynaptic D2 and A2A receptors 
regulate endocannabinoid release and eCB-LTD positively and negatively, respectively, 
by modulating mGluR signaling through regulator of G protein signaling 4 (RGS4) [31]. 
Enzymatic activity of DGLα is reduced after phosphorylation by CaMKII [49], 
suggesting the possibility that DGLα might be regulated by CaMKII-involving signals 
under physiological conditions. Presynaptic CB1 receptor signaling is influenced by the 
activity of colocalized presynaptic receptors. In the hippocampus, tonic activation of A1 
receptors by endogenous adenosine inhibits presynaptic CB1 signaling [50]. Because 
CB1 and A1 receptors are both Gi/o-coupled, it is conceivable that they use overlapping 
sets of Gα subunits and interact with each other.  
 Considering that the endocannabinoid system contributes to many brain 
functions including learning, memory, stress regulation and analgesia, its plastic 
changes induced by environmental factors are clinically important. One such factor is 
stress. There is growing evidence for functional interaction between the 
endocannabinoid system and activity along the HPA axis. The endocannabinoid system 
plays a key role in regulating the HPA axis under both basal and stressful conditions. It 
was proposed that a tonic level of anandamide within the basolateral amygdala provides 
a steady-state inhibition of HPA axis activity, and that glucocorticoid-induced 2-AG 
release from paraventricular nucleus neurons mediates rapid negative feedback effects 
of glucocorticoids on the HPA axis [37]. Conversely, stress-induced HPA axis activity 
alters the endocannabinoid system, either positively or negatively depending on the 
brain region, age and conditions of stress, in several brain regions including the 
hippocampus, amygdala, hypothalamus, nucleus accumbens and prefrontal cortex 
[6,37,51]. For example, repetitive immobilization stress impaired DSI/DSE by 
down-regulating CB1 receptors in the paraventricular nucleus of the hypothalamus [52], 
whereas chronic stress enhanced DSI partially by down-regulating MGL in the 
basolateral amygdala [53]. Interestingly, in vivo recordings of medial prefrontal cortex 
(mPFC)-evoked spike probability from the bed nucleus of the stria terminalis showed 
that acute restraint stress switched CB1-dependent plasticity from LTD to LTP, and that 
the stress-elicited shift in plasticity was controlled by CB1 receptors on excitatory 
terminals [54]. Mechanisms of these stress-induced plastic changes in the 
endocannabinoid system remain to be elucidated. 
 A possible relationship between the endocannabinoid system and psychiatric 
disorders has also been suggested, by exploring genetic morphisms in the human genes 
for the CB1 receptor and FAAH [55], and by examining eCB-STD/LTD in animal 
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models of psychiatric disorders including autism, schizophrenia and Fragile X 
syndrome [56-60]. In these animal models, alteration in DSI, mGluR-driven eCB-STD, 
eCB-LTD or the endocannabinoid tone has been reported. Further studies are required to 
understand the mechanisms that cause these alterations. 
 
Conclusions 
The endocannabinoid 2-AG plays an important role as a retrograde messenger at both 
excitatory and inhibitory synapses. It is synthesized and released from postsynaptic 
neurons in an activity-dependent manner, and suppresses transmitter release transiently 
(eCB-STD) or persistently (eCB-LTD). Although considerable progress has been made 
in recent years with regard to the molecular mechanisms of eCB-STD and eCB-LTD, 
several questions remain unsolved. First, the enzyme that produces DG upon Ca2+ 
elevation has not been identified. Second, it is not determined whether 2-AG can move 
across postsynaptic and presynaptic membranes, as well as the synaptic cleft, freely or 
requires some special machinery. Third, presynaptic mechanisms of eCB-LTD are not 
completely clear. Fourth, anandamide synthetic pathways are not fully understood. 
Although accumulating evidence suggests that the endocannabinoid system plays a role 
in many brain functions, and can be up- or down-regulated by a variety of factors, the 
precise mechanisms are poorly understood. Of note, the endocannabinoid system 
contributes to the regulation of the HPA axis and stress response and, conversely, 
undergoes plastic changes in response to stress condition. Understanding these features 
of the endocannabinoid system may be clinically important for the development of the 
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Molecular mechanisms of endocannabinoid-mediated short-term depression (eCB-STD). 
A: The production of diacylglycerol (DG) is induced by either a large Ca2+ elevation, 
which is caused by depolarization-induced activation of voltage-gated Ca2+ channels 
(VGCC), through unidentified mechanisms (red arrows), or strong activation of 
Gq/11-coupled receptors such as mGluRs and mAChRs through PLCβ (blue arrows). If 
weak activation of Gq/11-coupled receptors is combined with a small Ca
2+ elevation, 
both of which are subthreshold for DG production when given alone, receptor-driven 
PLCβ stimulation is enhanced by Ca2+ to produce DG (green arrow). DG is then 
converted to 2-AG by diacylglycerol lipase α (DGLα). 2-AG is released from the 
postsynaptic neuron, and activates presynaptic CB1 receptors to suppress transmitter 
release (STD). 2-AG is hydrolysed mostly by presynaptic monoacylglycerol lipase 
(MGL) and arachidonic acid (AA) is produced. B: Excitatory synaptic activity releases 
glutamate, which activates postsynaptic AMPA-type glutamate receptors (AMPARs) 
and mGluRs. Activation of AMPARs causes Ca2+ elevation through activating VGCCs. 
The resulting postsynaptic Ca2+ elevation and/or mGluR activation causes the release of 
2-AG through the mechanisms illustrated in A. 2-AG activates CB1 receptors on the 
same presynaptic terminals releasing glutamate (red arrow, homosynaptic) or 




Molecular mechanisms of endocannabinoid-mediated long-term depression (eCB-LTD). 
Afferent stimulation and/or postsynaptic depolarization induces 2-AG release by 
activating postsynaptic AMPARs, mGluRs and VGCCs. Mechanistically, this process is 
the same as that for eCB-STD, and includes CaER, basal RER and Ca2+-assisted RER. 
The released 2-AG then activates CB1 receptors on the same presynaptic terminals 
releasing glutamate (homosynaptic, red arrow) or neighboring terminals (blue arrow, 
heterosynaptic). LTD is induced when the activation of CB1 receptors is combined with 
some other factors in the presynaptic terminal, such as presynaptic electrical activity, 
Ca2+ influx through VGCCs or NMDA-type glutamate receptors (NMDARs) and the 






Functions of anandamide in the regulation of synaptic transmission. A: 
Anandamide-mediated LTD. Glutamate released by afferent stimulation activates 
postsynaptic mGluRs to induce anandamide production. Anandamide activates 
presynaptic CB1 receptors to induce presynaptic LTD (eCB-LTD), and activates 
postsynaptic TRPV1 channels to induce postsynaptic LTD that is expressed as a change 
in the function or number of postsynaptic glutamate receptors (TRPV1-LTD). B: 
Endocannabinoid tone generated by anandamide. At basal Ca2+ levels, anandamide is 
continuously produced and released. This anandamide-mediated endocannabinoid tone 







[1] Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M: 
Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 
2009, 89:309-380. 
 
[2] Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M: Endocannabinoids 
and retrograde modulation of synaptic transmission. Neuroscientist 2012, 
18:119-132. 
 
[3] Katona I, Freund TF: Multiple functions of endocannabinoid signaling in the 
brain. Annual review of neuroscience 2012, 35:529-558. 
 
[4] Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y: Endocannabinoid 
signaling and synaptic function. Neuron 2012, 76:70-81. 
 
[5] Piomelli D: More surprises lying ahead. The endocannabinoids keep us 
guessing. Neuropharmacology 2014, 76 Pt B:228-234. 
 
*[6] Iremonger KJ, Wamsteeker Cusulin JI, Bains JS: Changing the tune: Plasticity 
and adaptation of retrograde signals. Trends Neurosci 2013, 36:471-479. 
This review summarizes recent findings that endocannabinoid signaling is modulated by 
various neuromodulators and neural activity, and also exhibits plastic changes in 
response to in vivo experience.  
 
[7] Uchigashima M, Yamazaki M, Yamasaki M, Tanimura A, Sakimura K, Kano M, 
Watanabe M: Molecular and morphological configuration for 
2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-granule 
cell synapses in the dentate gyrus. J Neurosci 2011, 31:7700-7714. 
 
** [8] Tanimura A, Uchigashima M, Yamazaki M, Uesaka N, Mikuni T, Abe M, 
Hashimoto K, Watanabe M, Sakimura K, Kano M: Synapse type-independent 
degradation of the endocannabinoid 2-arachidonoylglycerol after 




This study demonstrates that MGL is present only in particular types of presynaptic 
terminals, yet eCB-STD is prolonged rather non-selectively at both MGL-positive and 
MGL-negative synapses in the cerebellum of MGL knockout mice. This study also 
shows that MGL expressed in astroglia significantly contributes to 2-AG degradation, 
because eCB-STD is prolonged in the cerebellum of conditional MGL knockout mice in 
which MGL is expressed only in astroglia.  
 
[9] Hashimotodani Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima 
T, Araishi K, Shin HS, Kano M: Phospholipase Cβ serves as a coincidence 
detector through its Ca2+ dependency for triggering retrograde 
endocannabinoid signal. Neuron 2005, 45:257-268. 
 
[10] Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, Wu D, Waku K, 
Sugiura T, Kano M: Synaptically driven endocannabinoid release requires 
Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase 
Cβ4 signaling cascade in the cerebellum. J Neurosci 2005, 25:6826-6835. 
 
[11] Sugawara Y, Echigo R, Kashima K, Minami H, Watanabe M, Nishikawa Y, 
Muranishi M, Yoneda M, Ohno-Shosaku T: Intracellular calcium level is an 
important factor influencing ion channel modulations by PLC-coupled 
metabotropic receptors in hippocampal neurons. Brain Res 2013, 1512:9-21. 
 
**[12] Hashimotodani Y, Ohno-Shosaku T, Tanimura A, Kita Y, Sano Y, Shimizu T, Di 
Marzo V, Kano M: Acute inhibition of diacylglycerol lipase blocks 
endocannabinoid-mediated retrograde signalling: Evidence for on-demand 
biosynthesis of 2-arachidonoylglycerol. J Physiol 2013, 591:4765-4776. 
This study demonstrates that eCB-STD is consistently blocked by acute 
pharmacological inhibition of DGL, supporting the “on-demand synthesis model” rather 
than the “pre-formed pool model”. A novel potent DGL inhibitor, OMDM-188, 
effectively blocks hippocampal DSI, striatal DSI, cerebellar DSI, cerebellar DSE, 
hippocampal mGluR-driven eCB-STD and cerebellar synaptically-driven eCB-STD 
after the treatment of slices or cultured neurons with OMDM-188 for 1 hr (slices) or 2-8 
minutes (cultured neurons).  
 
[13] Tanimura A, Yamazaki M, Hashimotodani Y, Uchigashima M, Kawata S, Abe M, 
Kita Y, Hashimoto K, Shimizu T, Watanabe M, Sakimura K et al: The 
13 
 
endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase 
α mediates retrograde suppression of synaptic transmission. Neuron 2010, 
65:320-327. 
 
[14] Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, Shen 
R, Zhang MY, Strassle BW, Lu P, Mark L et al: Loss of retrograde 
endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol 
lipase knock-out mice. J Neurosci 2010, 30:2017-2024. 
 
[15] Yoshino H, Miyamae T, Hansen G, Zambrowicz B, Flynn M, Pedicord D, Blat Y, 
Westphal RS, Zaczek R, Lewis DA, Gonzalez-Burgos G: Postsynaptic 
diacylglycerol lipase mediates retrograde endocannabinoid suppression of 
inhibition in mouse prefrontal cortex. J Physiol 2011, 589:4857-4884. 
 
[16] Zhong P, Pan B, Gao XP, Blankman JL, Cravatt BF, Liu QS: Genetic deletion 
of monoacylglycerol lipase alters endocannabinoid-mediated retrograde 
synaptic depression in the cerebellum. J Physiol 2011, 589:4847-4855. 
 
[17] Hashimotodani Y, Ohno-Shosaku T, Kano M: Presynaptic monoacylglycerol 
lipase activity determines basal endocannabinoid tone and terminates 
retrograde endocannabinoid signaling in the hippocampus. J Neurosci 2007, 
27:1211-1219. 
 
[18] Min R, Di Marzo V, Mansvelder HD: DAG lipase involvement in 
depolarization-induced suppression of inhibition: Does endocannabinoid 
biosynthesis always meet the demand? Neuroscientist 2010, 16:608-613. 
 
[19] Alger BE, Kim J: Supply and demand for endocannabinoids. Trends Neurosci 
2011, 34:304-315. 
 
[20] Min R, Testa-Silva G, Heistek TS, Canto CB, Lodder JC, Bisogno T, Di Marzo V, 
Brussaard AB, Burnashev N, Mansvelder HD: Diacylglycerol lipase is not 
involved in depolarization-induced suppression of inhibition at unitary 





[21] Zhang L, Wang M, Bisogno T, Di Marzo V, Alger BE: Endocannabinoids 
generated by Ca2+ or by metabotropic glutamate receptors appear to arise 
from different pools of diacylglycerol lipase. PLoS One 2011, 6:e16305. 
 
[22] Gerdeman GL, Ronesi J, Lovinger DM: Postsynaptic endocannabinoid release 
is critical to long-term depression in the striatum. Nat Neurosci 2002, 
5:446-451. 
 
*[23] Younts TJ, Chevaleyre V, Castillo PE: CA1 pyramidal cell theta-burst firing 
triggers endocannabinoid-mediated long-term depression at both somatic 
and dendritic inhibitory synapses. J Neurosci 2013, 33:13743-13757. 
For the induction of eCB-LTD, afferent stimulation is generally used. In contrast, this 
study demonstrates that eCB-LTD can be induced by theta-burst firing (TBF) of 
postsynaptic neurons. Moreover, TBF-induced eCB-LTD is expressed at both somatic 
and dendritic inhibitory synapses. 
 
[24] Castillo PE: Presynaptic LTP and LTD of excitatory and inhibitory synapses. 
Cold Spring Harbor perspectives in biology 2012, 4:a005728. 
 
[25] Singla S, Kreitzer AC, Malenka RC: Mechanisms for synapse specificity 
during striatal long-term depression. J Neurosci 2007, 27:5260-5264. 
 
[26] Heifets BD, Chevaleyre V, Castillo PE: Interneuron activity controls 
endocannabinoid-mediated presynaptic plasticity through calcineurin. Proc 
Natl Acad Sci U S A 2008, 105:10250-10255. 
 
[27] Sjostrom PJ, Turrigiano GG, Nelson SB: Neocortical LTD via coincident 
activation of presynaptic NMDA and cannabinoid receptors. Neuron 2003, 
39:641-654. 
 
[28] Ahumada J, Fernandez de Sevilla D, Couve A, Buno W, Fuenzalida M: 
Long-term depression of inhibitory synaptic transmission induced by 
spike-timing dependent plasticity requires coactivation of endocannabinoid 
and muscarinic receptors. Hippocampus 2013, 23:1439-1452. 
 
[29] Pan B, Hillard CJ, Liu QS: D2 dopamine receptor activation facilitates 
15 
 
endocannabinoid-mediated long-term synaptic depression of GABAergic 
synaptic transmission in midbrain dopamine neurons via cAMP-protein 
kinase A signaling. J Neurosci 2008, 28:14018-14030. 
 
[30] Chiu CQ, Puente N, Grandes P, Castillo PE: Dopaminergic modulation of 
endocannabinoid-mediated plasticity at GABAergic synapses in the 
prefrontal cortex. J Neurosci 2010, 30:7236-7248. 
 
**[31] Lerner TN, Kreitzer AC: RGS4 is required for dopaminergic control of 
striatal LTD and susceptibility to Parkinsonian motor deficits. Neuron 2012, 
73:347-359. 
This study demonstrates that striatal eCB-LTD is modulated by D2 and A2A receptors 
through RGS4. According to the model presented, D2 and A2A receptors oppositely 
modulate cAMP/PKA and high PKA activity inhibits mGluR signaling via RGS4. 
Inhibition of mGluR signaling prevents the production of 2-AG and anandamide.  
 
[32] Grueter BA, Brasnjo G, Malenka RC: Postsynaptic TRPV1 triggers cell 
type-specific long-term depression in the nucleus accumbens. Nat Neurosci 
2010, 13:1519-1525. 
 
[33] Chavez AE, Chiu CQ, Castillo PE: TRPV1 activation by endogenous 
anandamide triggers postsynaptic long-term depression in dentate gyrus. 
Nat Neurosci 2010, 13:1511-1518. 
 
[34] Puente N, Cui Y, Lassalle O, Lafourcade M, Georges F, Venance L, Grandes P, 
Manzoni OJ: Polymodal activation of the endocannabinoid system in the 
extended amygdala. Nat Neurosci 2011, 14:1542-1547. 
 
[35] Khlaifia A, Farah H, Gackiere F, Tell F: Anandamide, cannabinoid type 1 
receptor, and NMDA receptor activation mediate non-hebbian 
presynaptically expressed long-term depression at the first central synapse 
for visceral afferent fibers. J Neurosci 2013, 33:12627-12637. 
 
[36] Kim J, Alger BE: Reduction in endocannabinoid tone is a homeostatic 




[37] Hill MN, Patel S, Campolongo P, Tasker JG, Wotjak CT, Bains JS: Functional 
interactions between stress and the endocannabinoid system: From synaptic 
signaling to behavioral output. J Neurosci 2010, 30:14980-14986. 
 
[38] Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen 
PT, Ramesh D, Booker L, Burston JJ, Thomas EA et al: Chronic 
monoacylglycerol lipase blockade causes functional antagonism of the 
endocannabinoid system. Nat Neurosci 2010, 13:1113-1119. 
 
*[39] Freestone PS, Guatteo E, Piscitelli F, di Marzo V, Lipski J, Mercuri NB: 
Glutamate spillover drives endocannabinoid production and inhibits 
GABAergic transmission in the Substantia Nigra pars compacta. 
Neuropharmacology 2013, 79C:467-475. 
This is the first report suggesting the endocannabinoid tone mediated by 
N-arachidonoyldopamine (NADA), which is produced in a mGluR-dependent manner, 
suppresses GABAergic transmission in nigral dopamine neurons but not in adjacent 
non-dopaminergic neurons. The data show that DSI and the endocannabinoid tone are 
mediated by distinct endocannabinoids, that is, 2-AG and NADA, respectively. 
 
[40] Navarrete M, Araque A: Endocannabinoids potentiate synaptic transmission 
through stimulation of astrocytes. Neuron 2010, 68:113-126. 
 
[41] Min R, Nevian T: Astrocyte signaling controls spike timing-dependent 
depression at neocortical synapses. Nat Neurosci 2012, 15:746-753. 
 
[42] Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous 
DN, Mendizabal-Zubiaga J, Grandes P, Liu Q et al: Acute cannabinoids impair 
working memory through astroglial CB1 receptor modulation of 
hippocampal LTD. Cell 2012, 148:1039-1050. 
 
[43] Benard G, Massa F, Puente N, Lourenco J, Bellocchio L, Soria-Gomez E, Matias 
I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E et al: 
Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat 
Neurosci 2012, 15:558-564. 
 
[44] Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, Guijarro A, 
17 
 
Lodola A, Armirotti A, Garau G, Bandiera T et al: A catalytically silent 
FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci 2012, 
15:64-69. 
 
[45] Wang DJ, Yang D, Su LD, Xie YJ, Zhou L, Sun CL, Wang Y, Wang XX, Shen Y: 
Cytosolic phospholipase A2 alpha/arachidonic acid signaling mediates 
depolarization-induced suppression of excitation in the cerebellum. PLoS 
One 2012, 7:e41499. 
 
[46] Wang DJ, Su LD, Wang YN, Yang D, Sun CL, Zhou L, Wang XX, Shen Y: 
Long-term potentiation at cerebellar parallel fiber-purkinje cell synapses 
requires presynaptic and postsynaptic signaling cascades. J Neurosci 2014, 
34:2355-2364. 
 
[47] Morozov YM, Dominguez MH, Varela L, Shanabrough M, Koch M, Horvath TL, 
Rakic P: Antibodies to cannabinoid type 1 receptor co-react with 
stomatin-like protein 2 in mouse brain mitochondria. Eur J Neurosci 2013, 
38:2341-2348. 
 
[48] Leung K, Elmes MW, Glaser ST, Deutsch DG, Kaczocha M: Role of 
FAAH-like anandamide transporter in anandamide inactivation. PLoS One 
2013, 8:e79355. 
 
[49] Shonesy BC, Wang X, Rose KL, Ramikie TS, Cavener VS, Rentz T, Baucum AJ, 
2nd, Jalan-Sakrikar N, Mackie K, Winder DG, Patel S et al: CAMKII regulates 
diacylglycerol lipase-α and striatal endocannabinoid signaling. Nat Neurosci 
2013, 16:456-463. 
 
[50] Hoffman AF, Laaris N, Kawamura M, Masino SA, Lupica CR: Control of 
cannabinoid CB1 receptor function on glutamate axon terminals by 
endogenous adenosine acting at A1 receptors. J Neurosci 2010, 30:545-555. 
 
*[51] Senst L, Bains J: Neuromodulators, stress and plasticity: A role for 
endocannabinoid signalling. J Exp Biol 2014, 217:102-108. 
This review summarizes the studies demonstrating the roles of the endocannabinoid 
signaling in the stress response, and the stress-induced plastic changes of the 
18 
 
endocannabinoid system.  
 
[52] Wamsteeker JI, Kuzmiski JB, Bains JS: Repeated stress impairs 
endocannabinoid signaling in the paraventricular nucleus of the 
hypothalamus. J Neurosci 2010, 30:11188-11196. 
 
[53] Patel S, Kingsley PJ, Mackie K, Marnett LJ, Winder DG: Repeated homotypic 
stress elevates 2-arachidonoylglycerol levels and enhances short-term 
endocannabinoid signaling at inhibitory synapses in basolateral amygdala. 
Neuropsychopharmacology 2009, 34:2699-2709. 
 
*[54] Glangetas C, Girard D, Groc L, Marsicano G, Chaouloff F, Georges F: Stress 
switches cannabinoid type-1 (CB1) receptor-dependent plasticity from LTD 
to LTP in the bed nucleus of the stria terminalis. J Neurosci 2013, 
33:19657-19663. 
The bed nucleus of the stria terminalis (BNST) is a key target of stress, and regulates 
the HPA axis. This study shows that acute stress reverses the CB1-dependent plasticity 
from LTD to LTP in the BNST, and that the stress-elicited LTP involves CB1 receptors 
located on excitatory terminals. 
 
[55] Hillard CJ, Weinlander KM, Stuhr KL: Contributions of endocannabinoid 
signaling to psychiatric disorders in humans: Genetic and biochemical 
evidence. Neuroscience 2012, 204:207-229. 
 
[56] Du H, Kwon IK, Kim J: Neuregulin-1 impairs the long-term depression of 
hippocampal inhibitory synapses by facilitating the degradation of 
endocannabinoid 2-AG. J Neurosci 2013, 33:15022-15031. 
 
[57] Foldy C, Malenka RC, Sudhof TC: Autism-associated neuroligin-3 mutations 
commonly disrupt tonic endocannabinoid signaling. Neuron 2013, 
78:498-509. 
 
[58] Maccarrone M, Rossi S, Bari M, De Chiara V, Rapino C, Musella A, Bernardi G, 
Bagni C, Centonze D: Abnormal mGlu 5 receptor/endocannabinoid coupling 




 [59] Zhang L, Alger BE: Enhanced endocannabinoid signaling elevates neuronal 
excitability in fragile X syndrome. J Neurosci 2010, 30:5724-5729. 
 
[60] Jung KM, Sepers M, Henstridge CM, Lassalle O, Neuhofer D, Martin H, Ginger 
M, Frick A, DiPatrizio NV, Mackie K, Katona I et al: Uncoupling of the 
endocannabinoid signalling complex in a mouse model of fragile X 











































































Figure 3_Ohno-Shosaku & Kano
